reports
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
USARAD, Nanox’s Teleradiology Subsidiary, Awarded Accreditation from T...
USARAD, Nanox’s Teleradiology Subsidiary, Awarded Accreditation from The Joint Commission Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., a leading provider of teleradiology services, has earned The Joint Commission’s Gold Seal of Approval® for Ambulatory Health Care Accreditation for the sixth time by demonstrating continu...
First Merchants Corporation Announces Cash Dividend
First Merchants Corporation Announces Cash Dividend MUNCIE, Ind., May 08, 2024 (GLOBE NEWSWIRE) -- First Merchants Corporation declared a cash dividend on May 7, 2024 of $0.35 per share. The dividend is payable on June 21, 2024, to shareholders of record as of June 7, 2024. For purposes of broker trading, the ex-date of the cash dividend is June 6, 2024. About First Merchants Corporation: First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service bank charter, First Merchants Bank. The Bank also operates as First...
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™...
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’s AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWS...
BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla to Participate in the Citizens JMP Life Sciences Conference SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one investor meetingsDate: Monday, ...
Intermex Reports First Quarter Results
Intermex Reports First Quarter Results Company generates strong earnings and margins, continued execution of omnichannel strategy Company to Host Conference Call Today at 9 a.m. ET MIAMI, May 08, 2024 (GLOBE NEWSWIRE) -- International Money Express, Inc. (NASDAQ: IMXI) (“Intermex” or the “Company”), one of the nation’s leading omnichannel money transfer services to Latin America and the Caribbean, today reported strong operating results for the first quarter of 2024. Financial performance highlights for the first quarter of 2024 compared with the same period last year are: Revenues of...
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and...
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2024, and provide...
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM35...
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to deliv...
Clene Reports First Quarter 2024 Financial Results and Recent Operatin...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p
LGI Homes Announces its Second Community in the Modesto Market
LGI Homes Announces its Second Community in the Modesto Market RIVERBANK, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced the opening of its second community in the Modesto, California, market, . This incredible community offers a variety of one and two-story homes and is located northeast of Modesto in the friendly town of Riverbank. “We are excited to be a part of the tremendous growth here in Riverbank. Diamond Bar East is so close to everything and offers an easy commute to the Bay Area. However, you don’t need to go anywhere because everything...
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2...
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024. Webcast InformationDate: Tuesday, May 14...
SRAX Signs Agreement to Merge with DNA Holdings
SRAX Signs Agreement to Merge with DNA Holdings Westlake Village, CA, May 08, 2024 (GLOBE NEWSWIRE) -- SRAX Inc. (OTC: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, announced today it has entered into a definitive merger agreement with DNA Holdings Venture Inc. pursuant to which the shareholders of DNA will become the majority owners of SRAX’s outstanding common stock as more fully described below upon the closing of the merger. DNA has been a long term investor in SRAX and currently owns approximate...
Horizon Aircraft Provides Update on Technical Flight Testing Progress
Horizon Aircraft Provides Update on Technical Flight Testing Progress ~ Continued Flight-Testing Progress Approaching Full Transition to Forward Flight of the Company’s Large-Scale Prototype eVTOL Aircraft ~ ~ Dynamic Video Footage of Most Recent Flight Test ~ ~ Continuing Detailed Design of the Full-Scale Cavorite X7 Hybrid eVTOL Aircraft, on Track for Completion and Testing in 2026 ~ TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft Ltd. (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon” or the “Company”), a leading hybrid electric Vertical TakeOff and Landing...
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infe...
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. “We thank the China National Intellectual Property Administration for their recognition of the significant potenti...
Lion One Drills 4.8 m of 30.48 g/t Gold in Near-Mine Expansion at Tuva...
North Vancouver, British Columbia--(Newsfile Corp. - May 8, 2024) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) (ASX: LLO) ("Lion One" or the "Company") is pleased to report significant new high-grade gold results from near-mine expansion drilling at its 100% owned Tuvatu Alkaline Gold Project in Fiji.Assay results are presented here for near-mine expansion drilling in the Murau down-dip extension and SKL areas of Tuvatu. Both areas are outside the current mine plan yet are close to current underground workings and are being brought into the mine plan for late 2024 and 2025. The Murau d...
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the , the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually. Presentation Details Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDTSession: Po...
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and I...
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in May: Pharma Partnering U.S. Summit (May 14-15, 2024) Format: In-personLocation: San Diego, California Lisata Representative: Tariq Imam, VP of Business Development ...
Aspira Women’s Health to Announce First Quarter Earnings Results and H...
Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15 AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a...
TSS, INC. TO REPORT FIRST QUARTER 2024 RESULTS ON TUESDAY, MAY 15th, ...
TSS, INC. TO REPORT FIRST QUARTER 2024 RESULTS ON TUESDAY, MAY 15th, 2024 ROUND ROCK, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- TSS, Inc. (Other OTC: TSSI), a data center services company that integrates high-performance computing infrastructure and software, will report financial results for its first quarter 2024 on Tuesday May 14th, 2024. The Company will conduct a conference call at 4.30 p.m. eastern time that day. To participate on the conference call, please dial 1-888-596-4144 toll free from the U.S., or 1-646-968-2525 for international calle...
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024 AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: Nanomedicines: Past, Present, Future. For additional information please go to: . Dr. Hu is an experienced Biomaterial Scientist with expertise in nanomedicine, biologics, vaccines, cell, in vivo, gene therapy, drug development processes. He has great passion for innovative biotherapeutics and leading scientific ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.